Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Fusi

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<sup>V600</sup> mutant advanced melanoma (INTERIM)Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.
Cancer Cell|December 16, 2014
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaMaria Romina Girotti, Filipa Lopes, Natasha Preece, et al.
Cancer Cell|March 16, 2017
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant MelanomaMaria Romina Girotti, Filipa Lopes, Natasha Preece, et al.
Nature Communications|November 10, 2016
Vasculogenic mimicry in small cell lung cancerStuart C Williamson, Robert L Metcalf, Francesca Trapani, et al.
Nature Communications|February 11, 2017
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitorsMoritz Schütte, Thomas Risch, Nilofar Abdavi-Azar, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<sup>V600</sup> mutant advanced melanoma (INTERIM)Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.
Cancer Cell|December 16, 2014
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaMaria Romina Girotti, Filipa Lopes, Natasha Preece, et al.
Cancer Cell|March 16, 2017
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant MelanomaMaria Romina Girotti, Filipa Lopes, Natasha Preece, et al.
Nature Communications|November 10, 2016
Vasculogenic mimicry in small cell lung cancerStuart C Williamson, Robert L Metcalf, Francesca Trapani, et al.
Nature Communications|February 11, 2017
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitorsMoritz Schütte, Thomas Risch, Nilofar Abdavi-Azar, et al.
Pageof 5